title: The business case for quality improvement: oral anticoagulation for atrial fibrillation.
abstract: BACKGROUND
  The potential to save money within a short time frame provides a more compelling "business case" for quality improvement than merely demonstrating cost-effectiveness. Our objective was to demonstrate the potential for cost savings from improved control in patients anticoagulated for atrial fibrillation.
  
  
  RESULTS
  Our population consisted of 67 077 Veterans Health Administration patients anticoagulated for atrial fibrillation between October 1, 2006, and September 30, 2008. We simulated the number of adverse events and their associated costs and utilities, both before and after various degrees of improvement in percent time in therapeutic range (TTR). The simulation had a 2-year time horizon, and costs were calculated from the perspective of the payer. In the base-case analysis, improving TTR by 5% prevented 1114 adverse events, including 662 deaths; it gained 863 quality-adjusted life-years and saved $15.9 million compared with the status quo, not accounting for the cost of the quality improvement program. Improving TTR by 10% prevented 2087 events, gained 1606 quality-adjusted life-years, and saved $29.7 million. In sensitivity analyses, costs were most sensitive to the estimated risk of stroke and the expected stroke reduction from improved TTR. Utilities were most sensitive to the estimated risk of death and the expected mortality benefit from improved TTR.
  
  
  CONCLUSIONS
  A quality improvement program to improve anticoagulation control probably would be cost-saving for the payer, even if it were only modestly effective in improving control and even without considering the value of improved health. This study demonstrates how to make a business case for a quality improvement initiative.
authors.affiliation: Center for Health Quality, Outcomes, and Economic Research, Bedford VA Medical Center, 200 Springs Road, Bedford, MA 01730, USA. adamrose@bu.edu
authors.forename: Adam J
authors.initials: AJ
authors.lastname: Rose
authors.forename: Dan R
authors.initials: DR
authors.lastname: Berlowitz
authors.forename: Arlene S
authors.initials: AS
authors.lastname: Ash
authors.forename: Al
authors.initials: A
authors.lastname: Ozonoff
authors.forename: Elaine M
authors.initials: EM
authors.lastname: Hylek
authors.forename: Jeremy D
authors.initials: JD
authors.lastname: Goldhaber-Fiebert
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000191:economics* / Q000401:mortality / Q000503:physiopathology; D003365:Costs and Cost Analysis; D005500:Follow-Up Studies; D006470:Hemorrhage; D006801:Humans; D008297:Male; D018803:Models, Economic; D058996:Quality Improvement; D012306:Risk; D020521:Stroke; D016019:Survival Analysis; D058014:Veterans Health; D014859:Warfarin / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D014859:Warfarin